These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29878660)

  • 21. Preclinical and clinical gene therapy for haemophilia.
    Chuah MK; Collen D; Vandendriessche T
    Haemophilia; 2004 Oct; 10 Suppl 4():119-25. PubMed ID: 15479384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver Gene Therapy: Reliable and Durable?
    Herzog RW; Pierce GF
    Mol Ther; 2019 Nov; 27(11):1863-1864. PubMed ID: 31630963
    [No Abstract]   [Full Text] [Related]  

  • 23. Gene therapy for haemophilia.
    Murphy SL; High KA
    Br J Haematol; 2008 Mar; 140(5):479-87. PubMed ID: 18275425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
    Van Damme A; Chuah MK; Collen D; VandenDriessche T
    Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemophilias A and B.
    Bolton-Maggs PH; Pasi KJ
    Lancet; 2003 May; 361(9371):1801-9. PubMed ID: 12781551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induced human pluripotent stem cells and advanced therapies: future perspectives for the treatment of haemophilia?
    Liras A
    Thromb Res; 2011 Jul; 128(1):8-13. PubMed ID: 21396685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.
    Pierce GF; Lillicrap D; Pipe SW; Vandendriessche T
    J Thromb Haemost; 2007 May; 5(5):901-6. PubMed ID: 17459005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging therapies for haemophilia - Global perspective.
    Mahlangu J; Cerquiera M; Srivastava A
    Haemophilia; 2018 May; 24 Suppl 6():15-21. PubMed ID: 29878661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent progress in gene therapy for hemophilia.
    Chuah MK; Nair N; VandenDriessche T
    Hum Gene Ther; 2012 Jun; 23(6):557-65. PubMed ID: 22671033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project.
    Iorio A; Skinner MW; Clearfield E; Messner D; Pierce GF; Witkop M; Tunis S;
    Haemophilia; 2018 Jul; 24(4):e167-e172. PubMed ID: 29781145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy for haemophilia "A" and "B": efficacy, safety and immune consequences.
    Chuah MK; Vandendriessche T
    Bull Mem Acad R Med Belg; 2007; 162(5-6):357-61. PubMed ID: 18405006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy for hemophilia.
    Lynch CM
    Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy for hemophilia.
    Chuah MK; Collen D; VandenDriessche T
    J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene therapy strategies for hemophilia: benefits versus risks.
    Petrus I; Chuah M; VandenDriessche T
    J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy.
    Youjin S; Jun Y
    Biotechnol Lett; 2009 Mar; 31(3):321-8. PubMed ID: 18979215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
    Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
    Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
    Monahan PE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.